#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Li-Fraumeni syndrome Transferrin decreased Ornithine transcarbamoylase deficiency Partial lipodystrophy Cardiomyopathy Breast angiosarcoma Corneal neovascularisation Intracranial germ cell tumour Rectal cancer Breast angiosarcoma metastatic Cutaneous calcification Dilated cardiomyopathy Glomerulonephritis minimal lesion Short-bowel syndrome Necrotising myositis More trials…

    Learn about Rare Diseases

    Haemophilia A without inhibitors – Basic Information Sarcoidosis – Basic Information Gaucher’s disease type I – Life with Disease Methylmalonic acidaemia – Diagnostics Hyperoxaluria – Diagnostics X-linked lymphoproliferative syndrome – Treatment Kearns-Sayre syndrome – Diagnostics Ewing’s sarcoma metastatic – Treatment Pleomorphic leiomyosarcoma – Diagnostics Systemic sclerosis pulmonary – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Pyridoxine Hydrochloride Bp Heparin Arrhenatherum Elatius Navtemadlin TAGRAXOFUSP Cilastatin Ds-2325A Valganciclovir Hydrochloride Zasocitinib ALENDRONATE SODIUM TRIHYDRATE ZIGAKIBART GOCATAMIG LY3372993 Domperidone Ceftazidime Pentahydrate Azd8630 GSKVX000000034792 Flutemetamol (18F) Prasugrel Hydrobromide Anhydrous Docetaxel More therapies…

    Learn about Your Condition

    Graft infection Thalassaemia beta Conjunctivitis Eosinophilic oesophagitis Exfoliation glaucoma Pneumothorax Factor VIII deficiency Liposarcoma recurrent Ewing's sarcoma metastatic Organ donor Peritonitis Growth hormone deficiency Hyperphagia Appendicitis Haemophilia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Orszagos Onkologiai Intezet

Orszagos Onkologiai Intezet

Rath Gyorgy Utca 7-9, Kerulet, Budapest, 1122, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Lenalidomide
    • Rituximab
    • Tafasitamab
    Austria Belgium Czechia Denmark Finland France +10

  • Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Leuprorelin
    • Abemaciclib
    • Giredestrant
    Austria Belgium Finland France Germany Greece +7

  • Study of Pembrolizumab, Favezelimab, and Lenvatinib for Patients with Renal Cell Carcinoma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Quavonlimab
    • Favezelimab
    • Vibostolimab
    France Hungary The Netherlands Poland Spain

  • Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cisplatin
    • Pembrolizumab
    Austria Belgium France Germany Hungary Ireland +3

  • Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Enzalutamide
    • Pembrolizumab
    Austria Bulgaria Czechia France Germany Hungary +5

  • Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria France Germany Hungary Italy The Netherlands +4

  • Study of Pembrolizumab in Patients with Esophageal Cancer Undergoing Chemoradiotherapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Oesophageal carcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Cisplatin
    • Fluorouracil
    Belgium Czechia Denmark Estonia France Germany +4

  • Study of Chemotherapy With Pembrolizumab and Olaparib for Patients With Advanced Epithelial Ovarian Cancer Without BRCA Mutation

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Ovarian epithelial cancer
    Investigated Drugs:
    • Anhydrous Docetaxel
    • Olaparib
    • Bevacizumab
    Belgium Czechia France Germany Hungary Italy +2

  • Study of Navtemadlin as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

    Not recruiting

    4 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Loperamide
    • Loperamide Hydrochloride
    • Navtemadlin
    Austria Czechia Denmark Estonia Finland France +9

  • Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer recurrent
    Investigated Drugs:
    • Gallium (68Ga) Gozetotide
    • Piflufolastat (18F)
    • Darolutamide
    Austria Belgium Czechia Denmark Finland France +8
Previous Page
1 … 14 15 16 17
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!